Collaboration|HTA

Cross-company collaboration on a NICE HTA


Seamless collaboration with Delta Hat to deliver NICE & SMC submissions under tight timelines…

Read more from Cross-company collaboration on a NICE HTA

Early Dialogue

HTA scientific advice for a cell therapy in lymphoma


Supporting Global and UK pharma with early dialogue in the UK and France…

Read more from HTA scientific advice for a cell therapy in lymphoma

UK Market Access

Post-Brexit access and regulatory landscape slide resource


Developing a succinct yet detailed training resource on the post-Brexit access and regulatory landscape for global roll-out across stakeholders in a Top 20 pharma company…

Read more from Post-Brexit access and regulatory landscape slide resource

Value Communication

Value proposition development for time critical EU commercial launch


Co-creating a compelling payer value proposition with stakeholders across an alliance of three pharma companies…

Read more from Value proposition development for time critical EU commercial launch

Value Communication

Large pre-launch value comms programme delivery


Pre-launch value communications materials delivered on time due to redthread’s diligent project management and proactive content development…

Read more from Large pre-launch value comms programme delivery

Collaboration|Value Communication

Collaborating in better teams, not bigger teams


Close collaboration with our health economics partners at Delta Hat ensured efficient delivery of pre-launch value communications and modelling deliverables…

Read more from Collaborating in better teams, not bigger teams

Value Communication

Payer value proposition in thyroid cancer


Rescuing a PVP initiated by another vendor in 6 weeks to hit critical global launch timings…

Read more from Payer value proposition in thyroid cancer

UK Market Access

MHRA Innovative Licensing and Access Pathway (ILAP) support


Developing an Innovation Passport (IP) application as the first step of the UK Innovative Licensing and Access Pathway (ILAP) process…

Read more from MHRA Innovative Licensing and Access Pathway (ILAP) support

HTA

Parallel SMC submissions in breast cancer


Leading parallel abbreviated submissions to achieve successful unrestricted access at target price…

Read more from Parallel SMC submissions in breast cancer

Collaboration|HTA

Cross-company collaboration on a NICE HTA


Seamless collaboration with Delta Hat to deliver NICE & SMC submissions under tight timelines…

Read more from Cross-company collaboration on a NICE HTA

Early Dialogue

HTA scientific advice for a cell therapy in lymphoma


Supporting Global and UK pharma with early dialogue in the UK and France…

Read more from HTA scientific advice for a cell therapy in lymphoma

UK Market Access

Post-Brexit access and regulatory landscape slide resource


Developing a succinct yet detailed training resource on the post-Brexit access and regulatory landscape for global roll-out across stakeholders in a Top 20 pharma company…

Read more from Post-Brexit access and regulatory landscape slide resource

Value Communication

Value proposition development for time critical EU commercial launch


Co-creating a compelling payer value proposition with stakeholders across an alliance of three pharma companies…

Read more from Value proposition development for time critical EU commercial launch

Value Communication

Large pre-launch value comms programme delivery


Pre-launch value communications materials delivered on time due to redthread’s diligent project management and proactive content development…

Read more from Large pre-launch value comms programme delivery

Collaboration|Value Communication

Collaborating in better teams, not bigger teams


Close collaboration with our health economics partners at Delta Hat ensured efficient delivery of pre-launch value communications and modelling deliverables…

Read more from Collaborating in better teams, not bigger teams

Value Communication

Payer value proposition in thyroid cancer


Rescuing a PVP initiated by another vendor in 6 weeks to hit critical global launch timings…

Read more from Payer value proposition in thyroid cancer

UK Market Access

MHRA Innovative Licensing and Access Pathway (ILAP) support


Developing an Innovation Passport (IP) application as the first step of the UK Innovative Licensing and Access Pathway (ILAP) process…

Read more from MHRA Innovative Licensing and Access Pathway (ILAP) support

HTA

Parallel SMC submissions in breast cancer


Leading parallel abbreviated submissions to achieve successful unrestricted access at target price…

Read more from Parallel SMC submissions in breast cancer